4α-PDD, 4α-phorbol-12,13-didecanoate; ABCB, ATP-binding cassette B1; AKT, protein kinase B; ALA, alpha lipoic acid; AMPK, AMP-activated protein kinase; APB, aminoethoxydiphenyl borate; ATP, adenosine triphosphate; CBD, cannabidiol; CRAC, Ca2+ release-activated Ca2+ channel; CaR, calcium-sensing receptor; CaSR, calcium sensing receptor; Cancer progression; DAG, diacylglycerol; DBTRG, Denver Brain Tumor Research Group; ECFC, endothelial colony-forming cells; ECM, enhanced extracellular matrix; EGF, epidermal growth factor; EMT, epithelial­mesenchymal transition; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; ETS, erythroblastosis virus E26 oncogene homolog; FAK, focal adhesion kinase; GADD, growth arrest and DNA damage-inducible gene; GC, gastric cancer; GPCR, G-protein coupled receptor; GSC, glioma stem-like cells; GSK, glycogen synthase kinase; HCC, hepatocellular carcinoma; HIF, hypoxia-induced factor; HSC, hematopoietic stem cells; IP3R, inositol triphosphate receptor; Intracellular mechanism; KO, knockout; LOX, lipoxygenase; LPS, lipopolysaccharide; LRP, lipoprotein receptor-related protein; MAPK, mitogen-activated protein kinase; MLKL, mixed lineage kinase domain-like protein; MMP, matrix metalloproteinases; NEDD4, neural precursor cell expressed, developmentally down-regulated 4; NFAT, nuclear factor of activated T-cells; NLRP3, NLR family pyrin domain containing 3; NO, nitro oxide; NSCLC, non-small cell lung cancer; Nrf2, nuclear factor erythroid 2-related factor 2; P-gp, P-glycoprotein; PCa, prostate cancer; PDAC, pancreatic ductal adenocarcinoma; PHD, prolyl hydroxylases; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PKD, polycystic kidney disease; PLC, phospholipase C; Programmed cancer cell death; RNS/ROS, reactive nitrogen species/reactive oxygen species; RTX, resiniferatoxin; SMAD, Caenorhabditis elegans protein (Sma) and mothers against decapentaplegic (Mad); SOCE, store operated calcium entry; SOR, soricimed; STIM1, stromal interaction molecules 1; TEC, tumor endothelial cells; TGF, transforming growth factor-ß; TNF-α, tumor necrosis factor-α; TRP channels; TRPA/C/M/ML/N/P/V, transient receptor potential ankyrin/canonical/melastatin/mucolipon/NOMPC/polycystin/vanilloid; Targeted tumor therapy; Tumor microenvironment; Tumor-associated immunocytes; UPR, unfolded protein response; VEGF, vascular endothelial growth factor; VIP, vasoactive intestinal peptide; VPAC, vasoactive intestinal peptide receptor subtype; mTOR, mammalian target of rapamycin; pFRG/RTN, parafacial respiratory group/retrotrapezoid nucleus